



**Milestone**  
PHARMACEUTICALS

## **Milestone Pharmaceuticals to Host Mid-Year Update Conference Call**

August 6, 2019

**Montreal, QC, Canada, and Charlotte, NC, August 6, 2019** – Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that it will host a mid-year update conference call on Tuesday, August 13, 2019 at 8:00 a.m. Eastern Time.

To access the live call by phone, dial (800) 529-3311 (domestic) or (470) 495-9164 (international) and enter the passcode 9498516. A live webcast of the call can be accessed in the News & Events section of Milestone's website at [www.milestonepharma.com](http://www.milestonepharma.com). An archived replay of the webcast will be available on the same website for approximately 30 days following the call.

### **About Milestone Pharmaceuticals**

Milestone is a Phase 3 clinical stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil. Milestone is also planning to initiate a Phase 2 clinical trial in the second half of 2019 in atrial fibrillation, another rapid heart rate condition, and expect to subsequently initiate an additional Phase 2 clinical trial in angina in 2020 to establish proof-of-concept for the broader use of etripamil.

### **Contact:**

David Pitts  
Argot Partners  
212-600-1902  
[david@argotpartners.com](mailto:david@argotpartners.com)

**C** View original content to download multimedia: <http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-host-mid-year-update-conference-call-300896462.html>